Patents by Inventor Michaela BOWDEN

Michaela BOWDEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for diagnosing prostate cancer using a gene expression signature
    Patent number: 10900086
    Abstract: The present invention relates to compositions and methods and for the diagnosis, prognosis, and treatment of prostate cancer. The invention is based upon the identification of a gene expression signature that predicts the likelihood that prostate cancer will metastasize. Provided is a method of determining whether prostate cancer in a subject will metastasize. Also provided are compositions comprising a prostate cancer-associated gene. Also provided are kits comprising a package with a prostate cancer-associated gene.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 26, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michaela Bowden, Svitlana Tyekucheva, Massimo Loda, Lorelei Mucci
  • Biomarkers of tumor pharmacodynamic response
    Patent number: 8563254
    Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: October 22, 2013
    Assignee: Novartis AG
    Inventors: Michaela Bowden, Alan Buckler, Chantale T. Guy
  • BIOMARKERS OF TUMOR PHARMACODYNAMIC RESPONSE
    Publication number: 20110092508
    Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.
    Type: Application
    Filed: October 15, 2010
    Publication date: April 21, 2011
    Inventors: Michaela BOWDEN, Alan BUCKLER, Chantale T. GUY